Searchable abstracts of presentations at key conferences in endocrinology

ea0063p743 | Thyroid 2 | ECE2019

The prevalence of anti-parietal cell and tissue-transglutaminase antibodies in patients with autoimmune thyroid disease: a preliminary report

Rosenblum Rachel Chava , Rotman-Pikielny Pnina , Shapiro Menachem , Twito Orit

Background: The association between autoimmune thyroid disease (AITD) and other autoimmune diseases is well-known. The prevalence of concurrent autoimmune gastritis and celiac disease in AITD has been estimated at approximately 20–25% and 2–5% respectively. Although both conditions have significant morbidity including malignancy and may necessitate dietary modifications and endoscopic evaluation, no recommendation exists to screen AITD patients for these autoimmune d...

ea0063p50 | Adrenal and Neuroendocrine Tumours 1 | ECE2019

A seminoma with entrapped nerve ganglion masquerading as a paraganglioma

Rosenblum Rachel Chava , Atlan Karine , Diment Judith , Mazeh Haggi , Rotman-Pikielny Pnina , Twito Orit

Background: The differential diagnosis of retroperitoneal tumors includes lymphoid, germ cell and neurogenic tumors such as paraganglioma. Paragangliomas are rare neuroendocrine tumors of the autonomic nervous system, which may secrete catecholamines and their metabolites. Clinical features include sustained or paroxysmal hypertension, headaches, sweating and palpitations. Here we present an unusual case of a retroperitoneal tumor entrapping a sympathetic nerve ganglion and mi...

ea0056p1009 | Endocrine tumours and neoplasia | ECE2018

Bethesda System for Reporting Thyroid Cytopathology (BSRTC): Category III and IV Frequency and Risk of Malignancyin the Era of Molecular Testing and after the Reclassification of Non Invasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features (NIFTPs)

Rosenblum Rachel Chava , Shtabsky Alexander , Marmor Silvia , Trejo Leonor , Yaish Iris , Yehuda Moshe , Barnes Sophie , Stern Naftali , Silman Zmira , Tordjman Karen

Background: The BSRTC aimed to standardize thyroid cytopathology reporting while enabling stratification of risk of malignancy (ROM) in thyroid nodules. Observational studies have demonstrated varying ROM for the Bethesda III and IV categories, further affected by the recent exemption of NIFTP. Finally, molecular testing is becoming a reasonable alternative for evaluating ROM in categories III and IV.Objective: To retrospectively establish the use of Bet...